RENASCENT II: First in Human Evaluation of a Novel Sirolimus-Eluting Ultra-High Molecular Weight APTITUDE ® Bioresorbable Scaffold: 9-and 24-Months Imaging and Clinical Results.

CONCLUSIONS: In this multi-center prospective study, the APTITUDE® BRS was shown to be safe and effective in the treatment of single coronary lesions at 24-months clinical follow up. PMID: 32149709 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32149709?dopt=Abstract

Source: EuroIntervention - March 10, 2020 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research